Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Elan Corporation, plc (ELN) -- Ignore unavailable to you. Want to Upgrade?

To: nigel bates who wrote (3338)	10/2/2002 10:56:12 AM
From: Qualified Opinion	Respond to of 10345

Elan mulling exit from pain medications -source LONDON, Oct 2 (Reuters) - Irish pharmaceuticals company Elan is mulling an exit from the pain treatment business in a possible sale of its four main pain treatment medications, a source close to the company said on Wednesday. Elan, which announced the sale of its Abelcet antifungal treatment product for $370 million on Wednesday, may also put some or all of its Sonata, Skelaxin, Zanaflex and Naprelan drugs on the block as well. "They are still determining if it is a core activity," the source said. Elan's market capitalisation has tumbled from around $22 billion to under $500 million in the past year, following market fears about its accounting policies. reuters.co.uk